AMERICAN BIOMED, Minimally Invasive Technology (ABMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark S. who wrote (229)	3/21/1998 5:14:00 PM
From: Aishwarya	Read Replies (3) of 2887

Mark, this post should give an idea in a nutshell what kind of market our company is poised for THE WORLDWIDE MARKET FOR DILATION BALLOON CATHETERS Market Size and Growth: The total balloon catheter market was $1.4 billion in 1995; $798.9 billion in the United States and $577.2 billion abroad. Product Segments: Balloon catheters are classed by their method of navigation, size of the balloons, compliance of the balloons, and the amount of pressure needed for balloon inflation. Market Forecasts: Growth is currently forecasted at between 7.8% and 8.9% for PTCA balloon catheters. The peripheral PTA procedure is a still emerging segment; it is anticipated to grow at a 15% to 17% rate through 2000. Marketing, Sales and Distribution: Sales of PTCA and PTA dilatation balloon catheters are directed solely at interventional cardiac catheterization laboratories. Issues and Trends: Growth in dollar volume in the balloon angioplasty catheter segments is being strongly affected by two opposing trends. The Consumer U.S. demographics favor increasing numbers of angioplasty procedures. Industry Structure: There are five large suppliers of balloon catheter products: Boston Scientific Corp.'s SciMed Life Systems, Guidant Corp.'s Advanced Cardiovascular Systems, Cordis Corp., Medtronic, and Pfizer's Schneider subsidiary. Other Baxter, Arterial Vascular systems and a lot of intermediate players who are cashing in big time on such opportunities. This is a large industry and the sheer market size offers lots of possibilities for consolidation as well opportunities to market ABMI's extensive portfolio of products. Once it gets going it may be bye bye. But we will be able to tell those growth signs should they happen to come our way. For now i will be happy to be patient. GO ABMI Regards, Sri.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next